DexCom, Inc. (NASDAQ:DXCM) Shares Purchased by Stratos Wealth Partners LTD.

Stratos Wealth Partners LTD. grew its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 32.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,428 shares of the medical device company’s stock after acquiring an additional 845 shares during the period. Stratos Wealth Partners LTD.’s holdings in DexCom were worth $234,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of DXCM. Norges Bank bought a new stake in DexCom during the fourth quarter worth approximately $385,367,000. Woodline Partners LP bought a new stake in DexCom in the fourth quarter worth $63,338,000. Northern Trust Corp lifted its position in DexCom by 22.2% during the 4th quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company’s stock worth $322,454,000 after acquiring an additional 753,857 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in DexCom during the 4th quarter worth $41,295,000. Finally, GAMMA Investing LLC raised its position in shares of DexCom by 5,951.7% during the first quarter. GAMMA Investing LLC now owns 499,746 shares of the medical device company’s stock valued at $34,128,000 after buying an additional 491,488 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Stock Down 0.8%

NASDAQ:DXCM opened at $84.13 on Thursday. The company has a current ratio of 1.50, a quick ratio of 1.32 and a debt-to-equity ratio of 0.55. The stock has a fifty day simple moving average of $84.53 and a 200-day simple moving average of $80.09. The company has a market cap of $32.99 billion, a price-to-earnings ratio of 62.78, a price-to-earnings-growth ratio of 1.81 and a beta of 1.44. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $117.19.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a net margin of 12.90% and a return on equity of 30.05%. The company had revenue of $1.04 billion during the quarter, compared to analysts’ expectations of $1.02 billion. During the same quarter last year, the firm earned $0.32 EPS. DexCom’s revenue for the quarter was up 12.5% on a year-over-year basis. Analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have weighed in on DXCM shares. Robert W. Baird decreased their price objective on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research note on Friday, May 2nd. Morgan Stanley raised their price objective on shares of DexCom from $82.00 to $89.00 and gave the stock an “equal weight” rating in a report on Tuesday. Canaccord Genuity Group raised their price objective on shares of DexCom from $103.00 to $106.00 and gave the stock a “buy” rating in a report on Friday, May 2nd. Wall Street Zen downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research report on Sunday, June 29th. Finally, Mizuho lifted their target price on shares of DexCom from $95.00 to $100.00 and gave the stock an “outperform” rating in a report on Wednesday. Five equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, DexCom presently has an average rating of “Moderate Buy” and a consensus target price of $99.60.

Insiders Place Their Bets

In other news, EVP Sadie Stern sold 6,184 shares of the stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $85.11, for a total transaction of $526,320.24. Following the completion of the transaction, the executive vice president directly owned 109,621 shares in the company, valued at approximately $9,329,843.31. This represents a 5.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Mark G. Foletta sold 2,750 shares of the stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $83.13, for a total value of $228,607.50. Following the transaction, the director directly owned 56,621 shares in the company, valued at approximately $4,706,903.73. The trade was a 4.63% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 27,190 shares of company stock valued at $2,281,732. Corporate insiders own 0.32% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.